Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: Current concepts and controversies | Zendy

ScottE Eggener | Zendy; Gautam Jayram | Zendy; RussellZ Szmulewitz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: Current concepts and controversies

Author(s) -

ScottE Eggener,

Gautam Jayram,

RussellZ Szmulewitz

Publication year - 2010

Publication title -

indian journal of urology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.333

H-Index - 30

eISSN - 1998-3824

pISSN - 0970-1591

DOI - 10.4103/0970-1591.60449

Subject(s) - medicine , germ cell tumors , retroperitoneal lymph node dissection , chemotherapy , lymph node , oncology , radiology , primary tumor , stage (stratigraphy) , teratoma , dissection (medical) , disease , localized disease , metastasis , surgery , cancer , testicular cancer , biology , prostate cancer , paleontology

Approximately 30% of nonseminomatous germ-cell tumors (NSGCT) of the testis present with metastatic disease. In 1997, the International Germ Cell Cancer Collaborative Group (IGCCCG) stratified all patients with metastatic NSGCT into various risk groups based on serum tumor markers and presence of visceral disease. We review the literature and present optimal stage-dependent management strategies in patients with favorable-risk metastatic NSGCT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research